Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Hepatitis interferon treatment

Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA (2000) Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 7 428 34 Wong DK, Cheung AM, O Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 119 312-323... [Pg.242]

Davis, G. L. (1994). Prediction of response to interferon treatment of chronic hepatitis C. J. Hepatol. 21,1-3. [Pg.232]

C. D. Naylor, A.S. Detsky, and 1. Heathcote, Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B a meta-analysis. Ann Intern Med, 1993.119 312-23. [Pg.184]

Cinar T. Subacute thyroiditis in a patient with chronic hepatitis C during interferon treatment a case report. Ondokuz Mayis Univ Tip Derg 1999 16 62-6. [Pg.672]

Mekkakia-Benhabib C, Marcellin P, Colas-Linhart N, Castel-Nau C, Buyck D, Erlinger S, Bok B. Histoire nat-urelle des dysthyroidies survenant sous interferon dans le traitement des hepatites chroniques C. [Natural history of dysthyroidism during interferon treatment of chronic hepatitis C.] Ann Endocrinol (Paris) 1996 57(5) 419-27. [Pg.672]

Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000 15(3) 300-3. [Pg.711]

Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 443-51. [Pg.711]

M., Gruewald, K., Greenberg, H.B. Hepatitis G virus infection in hemodialysis patients and the effects of interferon treatment. Amer. X Gastroenterol. 1997 92 1986-1991... [Pg.461]

Cianciara, J., Laskus, T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig. Dis. Sci. 1995 40 1842-1844... [Pg.687]

The principles and results of interferon treatment in chronic viral hepatitis B and C have been discussed in detail, (s. pp 702, 707)... [Pg.854]

Positive serological markers of autoimmune hepatitis before treatment in patients with concomitant chronic hepatitis C are sometimes associated with further exacerbation of an underlying autoimmune liver disease during interferon alfa treatment. Of three patients with raised antimitochondrial antibodies (over 1 160), only the two patients with M2 (with or without M4 or M8) subtypes had biochemical exacerbation of cholestasis and an unfavorable response to interferon alfa (255). Although very few patients were investigated, determination of antibodies against submitochondrial particles may help to identify patients who are likely to have no benefit and even exacerbation of liver disease with interferon alfa. [Pg.1808]

Takeda A, Ikegame K, Kimura Y, Ogawa H, Kanazawa S, Nakamura H. Pleural effusion during interferon treatment for chronic hepatitis C. Hepatogastroenterology 2000 47(35) 1431-5. [Pg.1820]

Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001 85(10) 1171-3. [Pg.1820]

Taliani G, Duca F, dementi C, De Bac C. Platelet-associated immunoglobulin G, thrombocytopenia and response to interferon treatment in chronic hepatitis C. J Hepatol 1996 25(6) 999. [Pg.1825]

Farhat BA, Johnson PJ, Williams R. Hazards of interferon treatment in patients with autoimmune chronic active hepatitis. J Hepatol 1994 20(4) 560-1. [Pg.1825]

Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs. Br J Haematol 1996 94(3) 551-6. [Pg.1828]

Chan TM, Wu FC, Lau JY, Lok AS, Lai CL, Cheng IK. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997 12(7) 1414-19. [Pg.1830]

Liver carcinoma is an unexpected consequence of interferon beta in patients with chronic hepatitis C. However, the authors cited other published Japanese reports of hepatocellular carcinoma during or after interferon treatment. It is worth noting that interferon beta, but not interferon alfa, significantly increased serum interleukin-6 concentrations in patients with chronic hepatitis C (41), and that interleukin-6 has been suggested to promote the growth of hepatocellular carcinoma. [Pg.1833]

Dufour J, De LeUis R, Kaplan M. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998 43 2573-6. [Pg.1832]

Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998 27 1394-402. [Pg.1835]

Interferon-o, a 165 amino acid glycoprotein, is effective in the treatment of viral hepatitis C and B, myeloma, melanoma, and renal carcinoma. Little is known about the renal metabolism of interferon-a despite extensive studies in experimental animals. In patients with normal renal function, the serum peak level occurs 8 hours after a subcutaneous injection of 3x10 units of interferon-a. Terminal elimination half-life ranges from 4 to 16 hours and after 24 to 48 hours, the interferon molecule is undetectable in the serum [181]. A-interferon urinary level is undetectable. Some authors have suggested that, despite the lack of urinary excretion, the kidney could play a role in interferon-a metabolism [182]. Indeed, as far as hepatitis C treatment is concerned, dialysis patients often show a better response to therapy than non-dialysis patients. This better efficacy in dialysis patients is associated with an increase of the incidence of adverse effects. This observation raises the question of pharmacokinetic modifications. One study documented that clearance kinetics of interferon-a in patients with chronic renal failure are about half the rate of patients with normal renal function [183]. Indeed interferon is filtered by the glomeruli and largely absorbed and catabolized within tubular cells [184]. [Pg.364]

See other pages where Hepatitis interferon treatment is mentioned: [Pg.232]    [Pg.238]    [Pg.240]    [Pg.173]    [Pg.180]    [Pg.181]    [Pg.181]    [Pg.312]    [Pg.419]    [Pg.674]    [Pg.677]    [Pg.439]    [Pg.447]    [Pg.850]    [Pg.1799]    [Pg.1800]    [Pg.1824]    [Pg.1834]    [Pg.236]    [Pg.524]    [Pg.613]    [Pg.534]    [Pg.173]   
See also in sourсe #XX -- [ Pg.181 ]



SEARCH



Alpha-interferon hepatitis treatment

Hepatitis treatment

Hepatitis, interferons

© 2024 chempedia.info